Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kenon Holdings Ltd.KEN · Entity 9011 | Director | March 16, 2026 | March 16, 2026 |
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kenon Holdings Ltd.
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,002 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,002 |
TG THERAPEUTICS, INC.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,640 |
Reported balance
After 2026-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 5,000 · Balance 168,640 F1: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations. F2: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $54.92 to $54.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes shares of restricted Common Stock, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations.
F2: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $54.92 to $54.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes shares of restricted Common Stock, which vest over various time periods.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 5,000 | $54.96 | $274,800.00 |
DisclosureSEC source: 0001437749-26-030343 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,640 F1 · shares: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations. F2 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $54.92 to $54.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 450 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-026608 · rdgdoc.xml · nonDerivative · entry 3 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,640 F1 · shares: 1. Represents a bona fide gift by the Reporting Person to a 501(c)(3) institution. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction. F2 · balance_after: 2. Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-026608 · rdgdoc.xml · nonDerivative · entry 2 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,090 F1 · shares: 1. Represents a bona fide gift by the Reporting Person to a 501(c)(3) institution. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction. F2 · balance_after: 2. Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-026608 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,590 F1 · shares: 1. Represents a bona fide gift by the Reporting Person to a 501(c)(3) institution. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction. F2 · balance_after: 2. Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantStock Tracking Unit · Derivative | 8,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020673 · rdgdoc.xml · derivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires not disclosed F1 · derivative.exercise_price: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. F2 · derivative.exercise_date: Provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date, the STUs shall vest upon the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date, the STUs shall vest upon the first anniversary of the date of grant. Read SEC document |
| January 29, 2026 Filed Jan 29, 2026 22:24 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 13,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002439 · rdgdoc.xml · nonDerivative · entry 2 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,690 F1 · shares: Represents a bona fide gift by the Reporting Person to the Reporting Person's children. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 22:24 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002439 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,887 F1 · shares: Represents a bona fide gift by the Reporting Person to the Reporting Person's children. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:47 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 21,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020545 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,887 F1 · shares: Reflects a grant of restricted shares that will vest on June 12, 2026. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-007052 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,479 F1 · security: Reflects the transfer of shares as a bona fide gift to a 501(c)(3) charitable organization. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| November 12, 2024 Filed Nov 12, 2024 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-034595 · rdgdoc.xml · nonDerivative · entry 2 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,479 F3 · security: Reflects the transfer of shares as a bona fide gift to a 501(c)(3) charitable organization. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 25,000 | $30.20 | $754,875.00 |
DisclosureSEC source: 0001437749-24-034595 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,479 F1 · price: Reflects the weighted average sale price. The range of prices for the shares sold was $30.17 to $30.29. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 19, 2024 Filed Jun 20, 2024 22:04 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 22,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020847 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,479 F1 · shares: Reflects a grant of restricted shares that will vest on June 14, 2025. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 20:52 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 22,000 | $15.97 | $351,340.00 |
DisclosureSEC source: 0001437749-24-007662 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,229 F1 · shares: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold was $15.95 to $16.00. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 23:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 17,500 | $19.03 | $333,025.00 |
DisclosureSEC source: 0001437749-24-000900 · rdgdoc.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,229 F1 · shares: In connection with the vesting of 58,732 shares on January 4, 2024, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations. Mr. Charney had no discretion with respect to such sale, which was transacted in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold was $19.01 to $19.06. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-105383 · tm2327273-1_4seq1.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,729 F1 · shares: Reflects a grant of restricted shares that will vest on June 14, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 30,000 | $11.10 | $333,000.00 |
DisclosureSEC source: 0001104659-23-001900 · tm232483-1_4seq1.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,729 F1 · shares: In connection with the vesting of 100,878 shares on January 1, 2023, 30,000 shares were sold in order to cover the reporting person's income tax obligations. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold was $10.91 to $11.38. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:31 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 43,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082016 · tm2221660-1_4seq1.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,729 F1 · shares: Reflects a grant of restricted shares that will vest on June 15, 2023. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:25 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084256 · tm2120405d1_4seq1.xml · nonDerivative · entry 2 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,997 F3 · shares: Reflects a grant of restricted shares that will vest on June 18, 2025. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:25 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084256 · tm2120405d1_4seq1.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,997 F1 · shares: Reflects a grant of restricted shares that will vest on June 18, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 23:49 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-076543 · tm2022959-2_4.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,997 F1 · shares: Reflects a grant of restricted shares that will vest on June 22, 2023. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 21:10 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 27,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-010890 · section16.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,997 F1 · shares: Reflects a grant of restricted shares that will vest on June 13, 2022. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 26, 2018 Filed Jul 2, 2018 21:59 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007267 · section16.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,949 F1 · kind: Reflects a grant of restricted shares that will vest on June 26, 2021. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:11 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005707 · section16.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,949 F1 · kind: Reflects a grant of restricted shares that will vest on June 16, 2020. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods Read SEC document |
| April 04, 2017 Filed Apr 4, 2017 21:57 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 7,000 | $11.17 | $78,190.00 |
DisclosureSEC source: 0001654954-17-003070 · section16.xml · nonDerivative · entry 1 Charney Laurence N · CIK 0001407451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,949 F1 · kind: Sale of a total of 7,000 shares was made to satisfy Mr. Charney's income tax obligations from the vesting of 25,071 restricted stock shares in 2016. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.